Table 2.

NER biomarkers that predict cisplatin and Et-743 drug activity measured as correlations between mean “drug preference scores” and mean NER protein levels for subsets of cell lines

Protein*AllOvarian cancerColon cancerXP cell lines
XPA_1−0.370.510.100.67
XPA_2−0.260.550.100.64
XPC_1−0.230.36−0.260.85
XPC_2−0.150.14−0.260.85
XPF_1−0.170.56−0.030.93
XPF_2−0.260.62−0.280.90
XPG_1−0.210.15−0.520.88
XPG_2−0.140.39−0.600.91
  • NOTE: Drug preference score was calculated by subtracting the sensitivity [−log10(IC50)] to Et-743 from that to cisplatin. Correlation coefficient, shown in the table, is the correlation between the drug preference score and the XP protein expression levels.

  • Tissues-of-origin groups: All, all of the groups combined; Ovarian Cancer, ovarian cancer cell lines; Colon Cancer, colon cancer cell lines; XP cell lines, XP-deficient cell lines.

  • * Nucleotide excision repair proteins (XPA, XPC, XPF, and XPG) profiled across all of tissue-of-origin groups on the reverse-phase protein microarray in duplicates (_1, _2).